Detalhe da pesquisa
1.
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Ann Oncol
; 33(10): 1005-1020, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35914639
2.
A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors.
Ann Oncol
; 26(11): 2341-6, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26395347
3.
Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma.
Support Care Cancer
; 23(3): 621-6, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25142706
4.
Increased rates of local complication of central venous catheters in the targeted anticancer therapy era: a 2-year retrospective analysis.
Support Care Cancer
; 23(5): 1295-302, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25326782
5.
Hyponatremia is a predictor of hospital length and cost of stay and outcome in cancer patients.
Support Care Cancer
; 23(10): 3095-101, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25739755
6.
The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO).
Ann Oncol
; 25(1): 9-15, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24335854
7.
Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises.
J Biol Regul Homeost Agents
; 28(4): 555-63, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25620167
8.
Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma.
Br J Cancer
; 109(7): 1755-9, 2013 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24008663
9.
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib.
Br J Cancer
; 108(5): 1126-32, 2013 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-23511629
10.
Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells.
Br J Cancer
; 109(4): 1040-50, 2013 Aug 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-23887605
11.
Anti-EGFR therapy in oesophagogastric cancer: precise but not enough.
Ann Oncol
; 29(8): 1884-1885, 2018 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29873680
12.
Stevens-Johnson syndrome during nivolumab treatment of NSCLC.
Ann Oncol
; 29(1): 283-284, 2018 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29045532
13.
Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients.
Br J Cancer
; 106(5): 799-804, 2012 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-22315053
14.
Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab.
Ann Oncol
; 23(7): 1706-12, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22112971
15.
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
Ann Oncol
; 28(11): 2906, 2017 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28327895
16.
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
Ann Oncol
; 23(9): 2313-2318, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22396447
17.
Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study.
Ann Oncol
; 23(8): 2072-2077, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22219016
18.
Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients.
Br J Cancer
; 104(11): 1786-90, 2011 May 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-21559018
19.
Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients.
Ann Oncol
; 22(4): 897-902, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-20926544
20.
Transformation of Cancer Care during and after the COVID Pandemic, a point of no return. The Experience of Italy.
J Cancer Policy
; 29: 100297, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34316437